Aytu BioPharma and Lupin Pharma Canada announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu‘s Adzenys XR-ODT and Cotempla XR-ODT product lines in Canada. Lupin will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT, which is expected to occur over the next 18 to 24 months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AYTU: